Propionate metabolism-related genes demonstrate the potential to serve as prognostic and immunotherapeutic markers in osteosarcoma
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study identifies propionate metabolism genes, ABAT and ALDH7A1, as novel prognostic indicators for osteosarcoma (OS). These genes predict patient outcomes and immune response, offering potential therapeutic targets for OS treatment.
Area Of Science
- Oncology
- Metabolic Research
- Bioinformatics
Background
- Osteosarcoma (OS) metabolic processes are crucial for developing diagnostics and therapeutics.
- Propionate metabolism plays a significant role in certain cancers, suggesting its relevance in OS.
Purpose Of The Study
- To identify novel prognostic indicators for OS using gene expression and clinical data.
- To explore the role of propionate metabolism in OS and its association with patient prognosis and immune response.
Main Methods
- Analysis of public datasets to identify differentially expressed genes (DEGs) and propionate metabolism-associated genes.
- Construction of a risk model using LASSO-Cox regression, followed by immune cell infiltration and immunotherapy response assessment.
- Development of a prognostic nomogram and validation through cell assays for key identified genes.
Main Results
- Identified 18 DEGs related to propionate metabolism in OS.
- Developed a risk model based on two prognostic genes: 4-aminobutyrate aminotransferase (ABAT) and aldehyde dehydrogenase 7 family member A1 (ALDH7A1).
- Demonstrated significant differences in immune infiltration between high- and low-risk groups, impacting immunotherapy response. Knockdown of ABAT promoted OS cell growth and invasion.
Conclusions
- Propionate metabolism is relevant in OS, with ABAT and ALDH7A1 serving as novel gene signatures for clinical outcome prediction.
- The identified gene signature can distinguish OS patients with different clinical outcomes and tumor microenvironments.
- ABAT and ALDH7A1 show potential as therapeutic targets for osteosarcoma.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...